Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Incidence of Chronic spontaneous urticaria

7 evidence topics · 6 sources

United States: incidence of diagnosed CSU in three US databases, 2012 to 2018, Novartis-funded

“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The data identification period for Optum EHR and Optum CDM was from January 1, 2012 to December 31, 2018, and for MarketScan it was January 1, 2012 to December 31, 2017.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The target population was identified using three anonymized databases: Optum Electronic Health Record (EHR), Optum Clinformatics Data Mart (CDM), and Truven Health MarketScan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Incident cohorts included newly identified patients with the first urticaria or angioedema code within the year of interest and no codes 12 months prior to that year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In Optum EHR, the age- and sex-standardized incidence rate (95% CI) among adults and pediatric patients during the identification period was 0.039 (0.039–0.039) and 0.066 (0.065–0.067) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The age-standardized incidence rate (95% CI) of CSU among the adult and pediatric populations during the identification period in Optum CDM was 0.094 (0.093–0.095) and 0.109 (0.107–0.111) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In MarketScan, the age-standardized incidence rate (95% CI) of CSU among adults and pediatric patients during the identification period was 0.102 (0.097–0.107) and 0.097 (0.096–0.098) per 100 person-years, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study also reports for the first time, to the best of our knowledge, standard incidence rate of diagnosed CSU in the USA, with period estimates among adults ranging from 0.039 to 0.102 per 100 person-years in the three databases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

United States: combined adult and pediatric incidence of diagnosed CSU and annual trend, Novartis-funded study
Global: urticaria incidence in the Global Burden of Disease 2021 study